Resources from the same session
LBA43 - Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial
Presenter: Ramez Eskander
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
740MO - Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): Analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
Presenter: Mansoor Raza Mirza
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
742MO - Neoadjuvant immune checkpoint blockade in mismatch repair deficient endometrial cancer
Presenter: Marco de Bruyn
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
741MO - Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), demonstrates clinical activity in recurrent/progressive epithelial endometrial cancer (EEC): STRO-002-GM1 phase I dose expansion
Presenter: Bhavana Pothuri
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA43, 740MO, 742MO and 741MO
Presenter: Christian Marth
Session: Mini oral session - Gynaecological cancers
Resources:
Slides
Webcast
743MO - Efficacy and safety of QL1706 plus paclitaxel and cisplatin/carboplatin +/- bevacizumab (Bev) as 1L treatment in recurrent or metastatic cervical cancer (r/mCC): A single-arm, multicenter phase II study
Presenter: Danbo Wang
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
744MO - AdvanTIG-202: Phase II randomized, multicenter, open-label study of tislelizumab (TIS) with or without ociperlimab (OCI) in patients (pts) with previously treated recurrent/metastatic (R/M) cervical cancer (CC)
Presenter: Jung-Yun Lee
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
LBA44 - Camrelizumab plus famitinib versus camrelizumab alone and investigator’s choice of chemotherapy in women with recurrent or metastatic cervical cancer
Presenter: Xiaohua Wu
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Invited Discussant 743MO, 744MO and LBA44
Presenter: Alexandra Leary
Session: Mini oral session - Gynaecological cancers
Resources:
Slides
Webcast
LBA45 - Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa)
Presenter: Joyce Liu
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast